Table 2. Baseline laboratory data for CKD patients randomised to either ergocalciferol or placebo.
| Ergocalciferol (n = 20) | Placebo (n = 18) | p value | |
| Creatinine (mg/dl) | 2.3 (0.8) | 2.0 (1.0) | 0.60 |
| eGFR (ml/min/1.73 m2) | 33.0 (13.5) | 38.7 (15) | 0.39 |
| Stage of CKD | 0.33 | ||
| Stage 3 | 9 (45%) | 13 (72.2%) | |
| Stage 4 | 11 (55%) | 5 (27.8%) | |
| Hb (g/dl) | 12.8 (1.8) | 12.6 (1.4) | 0.63 |
| Calcium (mg/dl) | 8.8 (0.8) | 8.8 (0.8) | 0.74 |
| Phosphate (mg/dl) | 3.8 (0.6) | 3.5 (0.6) | 0.16 |
| Calcium phosphate product (mg2/dl2) | 33.0 (4.2) | 31.2 (5.1) | 0.25 |
| PTH (pg/L) | 102.8 (76.4) | 118.9 (103.8) | 0.60 |
| CRP (mg/L) | 7.6 (17.2) | 5.9 (9.8) | 0.71 |
| Urine P:CR | 190.8 (276.4) | 102.7 (147.0) | 0.32 |
| Total cholesterol (mg/dl) | 201 (53) | 185 (39) | 0.36 |
| High density lipoprotein cholesterol (mg/dl) | 57.5 (24.0) | 46.7 (15.9) | 0.20 |
Figures in brackets are standard deviation of the mean. eGFR = estimated glomerular filtration rate, 25 (OH) D = 25 hydroxy vitamin D, Hb = haemaglobin, PTH = parathyroid hormone, CRP = C reactive protein, P:CR = protein:creatinine ratio.